share_log

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target

HC Wainwright & Co.重申买入SAB Biotherapeutics,维持4美元的目标价格
Benzinga ·  2023/06/21 11:46

HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $4 price target.

HC Wainwright & Co. 分析师爱德华·怀特重申SAB Biotherapeutics(纳斯达克股票代码:SABS)的买入,并维持4美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发